Xu and colleagues published a preclinical report in Military Medicine Research describing a tumor-catalytic PANoptosis approach: ultrasound-activated piezoelectric nanocatalysts trigger simultaneous pyroptosis, apoptosis and necroptosis in cancer models. The platform uses mechanical energy to activate nanocatalysts that produce reactive species and inflammatory signals, driving broad-programmed cell death. Authors demonstrated tumor shrinkage and immune-stimulatory signatures in treated models, proposing the method as a local, non‑invasive adjunct to elicit immunogenic cell death. The approach aims to overcome single-pathway resistance by engaging multiple PANoptotic routes. Key translational hurdles include nanoparticle biodistribution, off‑target inflammation, device delivery parameters, and manufacturing scale-up. The team recommends optimization of safety margins and combination testing with checkpoint inhibitors to assess systemic antitumor immunity.